지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 저널정보
- 대한외과학회 Annals of Surgical Treatment and Research Annals of Surgical Treatment and Research Vol.94 No.6
- 발행연도
- 2018.6
- 수록면
- 306 - 311 (6page)
이용수
초록· 키워드
오류제보하기
Purpose: The aim of this study was to evaluate the long-term outcome of additional 4-week chemotherapy with capecitabine during the resting periods following a 6-week neoadjuvant chemoradiotherapy (NCRT) regimen, in patients with locally advanced rectal cancer.
Methods: Radiotherapy was delivered to the whole pelvis at a total dose of 50.4 Gy for 6 weeks. Oral capecitabine was administered at a dose of 825 mg/m2 twice daily for 10 weeks. Surgery was performed 2–4 weeks following the completion of chemotherapy.
Results: Between January 2010 and September 2011, 41 patients completed the scheduled neoadjuvant therapy and surgery. The pathologic complete response rate, 5-year overall survival, and 5-year disease-free survival rates were 22%, 85.4%, and 78.0%, respectively. The 5-year systemic recurrence and 5-year local recurrence rates were 22% and 0%, respectively.
Conclusion: Additional 4-week chemotherapy with capecitabine, during the resting periods following a 6-week NCRT regimen, has favorable long-term oncologic outcomes. Further randomized controlled trials are however necessary to evaluate if substantial improvement in local control is achieved with this additional chemotherapy modality for locally advanced rectal cancer.
Methods: Radiotherapy was delivered to the whole pelvis at a total dose of 50.4 Gy for 6 weeks. Oral capecitabine was administered at a dose of 825 mg/m2 twice daily for 10 weeks. Surgery was performed 2–4 weeks following the completion of chemotherapy.
Results: Between January 2010 and September 2011, 41 patients completed the scheduled neoadjuvant therapy and surgery. The pathologic complete response rate, 5-year overall survival, and 5-year disease-free survival rates were 22%, 85.4%, and 78.0%, respectively. The 5-year systemic recurrence and 5-year local recurrence rates were 22% and 0%, respectively.
Conclusion: Additional 4-week chemotherapy with capecitabine, during the resting periods following a 6-week NCRT regimen, has favorable long-term oncologic outcomes. Further randomized controlled trials are however necessary to evaluate if substantial improvement in local control is achieved with this additional chemotherapy modality for locally advanced rectal cancer.
목차
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Long-term oncologic outcomes of neoadjuvant concurrent chemoradiotherapy with capecitabine and radical surgery in locally advanced rectal cancer : 10-year experiences at a single institution
Annals of Surgical Treatment and Research
2016 .10
-
Effect of time interval between capecitabine intake and radiotherapy on local recurrence-free survival in preoperative chemoradiation for locally advanced rectal cancer
Radiation oncology journal : ROJ
2017 .01
-
A Phase II Study of Preoperative Chemoradiotherapy with Capecitabine Plus Simvastatin in Patients with Locally Advanced Rectal Cancer
Cancer Research and Treatment
2023 .01
-
A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer
Cancer Research and Treatment
2015 .01
-
Neoadjuvant chemoradiotherapy determines the prognostic impact of anastomotic leakage in advanced rectal cancer
Annals of Surgical Treatment and Research
2022 .10
-
Clinical characteristics of rectal cancer patients with neoadjuvant chemoradiotherapy: a nationwide population-based cohort study in South Korea
Annals of Surgical Treatment and Research
2021 .05
-
Organ Preservation Strategies After Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
Annals of Coloproctology
2019 .01
-
Are We Predicting Disease Progress of the Rectal Cancer Patients without Surgery after Neoadjuvant Chemoradiotherapy?
Cancer Research and Treatment
2018 .01
-
Oncologic effects of adjuvant chemotherapy in patients with ypT0-2N0 rectal cancer after neoadjuvant chemoradiotherapy and curative surgery: a meta-analysis
Annals of Surgical Treatment and Research
2020 .08
-
Role of Neoadjuvant Chemotherapy in the Management of Advanced Ovarian Cancer
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Neoadjuvant Therapy to Optimize Patients" Outcome: Localized advanced rectal cancer: chemoradiation vs. TNT
대한임상종양학회 학술대회지
2021 .06
-
Outcomes of Preoperative Chemoradiotherapy and Combined Chemotherapy with Radiotherapy Without Surgery for Locally Advanced Rectal Cancer
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Prognostic factors in patients with locally advanced breast cancer treated with neoadjuvant taxane-anthracycline combination chemotherapy
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2015 .12
-
Local Recurrence after Neoadjuvant Chemoradiotherapy And Rectal Excision in Rectal Cancer Patients When The Distal Resection Margin Is Compromised
대한외과학회 학술대회 초록집
2020 .11
-
Appropriate Timing of Surgery after Neoadjuvant Chemo-Radiation Therapy for Locally Advanced Rectal Cancer
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Recent Update of Total Neoadjuvant Therapy for Rectal Cancer
대한외과학회 학술대회 초록집
2022 .05
-
Capecitabine Pattern of Usage, Rate of Febrile Neutropaenia and Treatment Related Death in Asian Cancer Patients in Clinical Practice
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Benefits of Adjuvant Chemotherapy for Clinical T3-4N0 Rectal Cancer After Preoperative Chemoradiotherapy
전남의대학술지
2023 .01
-
Advances in surgery for locally advanced rectal cancer
Annals of Coloproctology
2022 .08
-
Early Systemic Failure After Preoperative Chemoradiotherapy for the Treatment of Patients With Rectal Cancer
Annals of Coloproctology
2019 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0